DK0839046T3 - TNF-receptor og steroidhormon i en kombinationsterapi - Google Patents

TNF-receptor og steroidhormon i en kombinationsterapi

Info

Publication number
DK0839046T3
DK0839046T3 DK95926883T DK95926883T DK0839046T3 DK 0839046 T3 DK0839046 T3 DK 0839046T3 DK 95926883 T DK95926883 T DK 95926883T DK 95926883 T DK95926883 T DK 95926883T DK 0839046 T3 DK0839046 T3 DK 0839046T3
Authority
DK
Denmark
Prior art keywords
tnf receptor
steroid hormone
relates
combination therapy
treatment
Prior art date
Application number
DK95926883T
Other languages
English (en)
Inventor
Alessandra Boe
Francesco Borrelli
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of DK0839046T3 publication Critical patent/DK0839046T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK95926883T 1995-07-14 1995-07-14 TNF-receptor og steroidhormon i en kombinationsterapi DK0839046T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/002767 WO1997003686A1 (en) 1995-07-14 1995-07-14 Tnf receptor and steroid hormone in a combined therapy

Publications (1)

Publication Number Publication Date
DK0839046T3 true DK0839046T3 (da) 2002-02-18

Family

ID=8166058

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95926883T DK0839046T3 (da) 1995-07-14 1995-07-14 TNF-receptor og steroidhormon i en kombinationsterapi

Country Status (12)

Country Link
US (1) US6225300B1 (da)
EP (1) EP0839046B1 (da)
JP (1) JP4011618B2 (da)
AT (1) ATE212231T1 (da)
AU (1) AU715260B2 (da)
DE (1) DE69525181T2 (da)
DK (1) DK0839046T3 (da)
ES (1) ES2171547T3 (da)
HK (1) HK1009403A1 (da)
IL (1) IL118789A0 (da)
WO (1) WO1997003686A1 (da)
ZA (1) ZA965891B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7012060B1 (en) * 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
NL1006876C2 (nl) 1997-08-28 1999-03-02 Schiphol Luchthaven Nv Platform voor het parkeren en afhandelen van vliegtuigen.
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1450839A4 (en) * 2001-11-06 2009-06-24 Serono Lab METHOD OF TREATING BREAST CANCER THAT MEETS OESTROGENES
WO2003066165A1 (en) * 2002-02-06 2003-08-14 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
CA2515539A1 (en) * 2003-02-28 2004-09-10 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
GEP20002142B (en) * 1991-01-18 2000-06-25 Amgen Inc Method for Treatment and Prevention of TNF Mediated Diseases
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0710121B1 (en) 1993-07-30 2000-10-11 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis

Also Published As

Publication number Publication date
ZA965891B (en) 1997-03-19
HK1009403A1 (en) 1999-06-04
ATE212231T1 (de) 2002-02-15
EP0839046B1 (en) 2002-01-23
JPH11509213A (ja) 1999-08-17
JP4011618B2 (ja) 2007-11-21
IL118789A0 (en) 1996-10-31
ES2171547T3 (es) 2002-09-16
US6225300B1 (en) 2001-05-01
AU715260B2 (en) 2000-01-20
DE69525181D1 (de) 2002-03-14
WO1997003686A1 (en) 1997-02-06
DE69525181T2 (de) 2002-08-14
AU3110995A (en) 1997-02-18
EP0839046A1 (en) 1998-05-06

Similar Documents

Publication Publication Date Title
EA200201000A1 (ru) Гормон-заместительная терапия
YU69000A (sh) Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe
MX9800348A (es) Inhibidores de adhesion celular.
EA199700135A1 (ru) Ингибиторы клеточной адгезии
MD1920F2 (ro) Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
RS20060348A (en) Extended use combination comprising estrogens and progestins
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
ATE217192T1 (de) Kombinationsprodukt zur kontrazeption enthaltend progesteronantagonisten und gestagenen
TR199802705T2 (xx) Progestojen-anti-progestojen k�r�
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
BR9509019B1 (pt) comprimido isento de solventes orgÂnicos.
AU3254395A (en) Use of a combination product that contains a competitive progesterone antagonist and a gestagen for the production of a pharmaceutical agent for treating endometriosis or leiomyomata uteri
HK1021539A1 (en) Androstene derivatives.
EA200301022A1 (ru) Гормональная заместительная терапия
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
CA2504697A1 (en) Methods for treating migraine
AU2732597A (en) Novel pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
DK0839046T3 (da) TNF-receptor og steroidhormon i en kombinationsterapi
SE9603725D0 (sv) New teatment
AU9363398A (en) Hepatitis c receptor protein cd81
KR960030947A (ko) src SH2 특이성 화합물의 골흡수 질환 치료 용도
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner